| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9005739 | Clinical Therapeutics | 2005 | 19 Pages |
Abstract
This meta-analysis of 34,668 patients receiving â¥1 week and up to 1 year of treatment found no evidence that lumiracoxib was associated with a significant increase in CV risk compared with naproxen, placebo, or all comparators (placebo, diclofenac, ibuprofen, celecoxib, rofecoxib, and naproxen).
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD Matchaba, PhD Gitton, MSc Krammer, MD Ehrsam, MD Sloan, PhD Olson, PhD Mellein, MSc Hoexter, MD Orloff, MD Garaud,